Hyperphenylalaninemia in Cerebral Malaria
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00338520|
Recruitment Status : Completed
First Posted : June 20, 2006
Last Update Posted : October 22, 2012
|Condition or disease|
|Plasmodium Falciparum Malaria|
|Study Type :||Observational|
|Actual Enrollment :||285 participants|
|Official Title:||Hyperphenylalaninemia in Cerebral Malaria|
|Study Start Date :||October 2007|
|Actual Primary Completion Date :||January 2012|
|Actual Study Completion Date :||January 2012|
Healthy Controls (HC)
Healthy control children will be enrolled from out-patient well-baby visits.
Uncomplicated Malaria (UM)
Febrile children admitted to the hospital with Plasmodium falciparum parasitemia, no other cause of fever identified, no evidence of severe malaria (as listed in Study Protocol, Section 5.2 under exclusion criteria for UM), and no co-infection with other malaria species will be enrolled in the UM group.
Cerebral Malaria (CM)
Comatose children admitted to the hospitals will be evaluated by the house physician and/or member of the study team. If lumbar puncture is obtained, the parent or guardian will be approached for permission to enroll the child into the study. Parasitemic children with no other cause of coma identified will included in the CM group.
Non-malaria CNS disease (NMC)
Children without parasitemia and diagnosed with a non-malaria cause of coma or CNS disease will be enrolled in the non-malaria CNS disease group.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00338520
|Hubert Kairuki Memorial University|
|Dar es Salaam, Tanzania|
|Principal Investigator:||Donald L Granger, M.D.||University of Utah, Division of Infectious Diseases|
|Principal Investigator:||Esther D. Mwaikambo, M.D.||Hubert Kairuki Memorial Hospital (HKMU)|